To further elucidate the role of HPAEC cytoskeletal machinery as an important feature and potential therapeutic target of EndoMT leading to endothelial dysfunction, an MLCK inhibitor was used to prevent MLC phosphorylation and actin-myosin cross-linking [33,34,35]. The gene discussed is MLC1; the disease is endothelial dysfunction.